BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Savardi A, Borgogno M, De Vivo M, Cancedda L. Pharmacological tools to target NKCC1 in brain disorders. Trends Pharmacol Sci 2021;42:1009-34. [PMID: 34620512 DOI: 10.1016/j.tips.2021.09.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development. Epilepsia 2022. [PMID: 35950617 DOI: 10.1111/epi.17376] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hartmann A, Nothwang HG. NKCC1 and KCC2: Structural insights into phospho-regulation. Front Mol Neurosci 2022;15:964488. [DOI: 10.3389/fnmol.2022.964488] [Reference Citation Analysis]
3 Lv H, Gu X, Shan X, Zhu T, Ma B, Zhang H, Bambini-junior V, Zhang T, Li W, Gao X, Li F. Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder. Front Immunol 2022;13:870577. [DOI: 10.3389/fimmu.2022.870577] [Reference Citation Analysis]
4 Szymanski J, Minichiello L. NKCC1 Deficiency in Forming Hippocampal Circuits Triggers Neurodevelopmental Disorder: Role of BDNF-TrkB Signalling. Brain Sciences 2022;12:502. [DOI: 10.3390/brainsci12040502] [Reference Citation Analysis]
5 van Andel DM, Sprengers JJ, Keijzer-veen MG, Schulp AJA, Lillien MR, Scheepers FE, Bruining H. Bumetanide for Irritability in Children With Sensory Processing Problems Across Neurodevelopmental Disorders: A Pilot Randomized Controlled Trial. Front Psychiatry 2022;13:780281. [DOI: 10.3389/fpsyt.2022.780281] [Reference Citation Analysis]
6 Serranilla M, Woodin MA. Striatal Chloride Dysregulation and Impaired GABAergic Signaling Due to Cation-Chloride Cotransporter Dysfunction in Huntington’s Disease. Front Cell Neurosci 2022;15:817013. [DOI: 10.3389/fncel.2021.817013] [Reference Citation Analysis]
7 Cherubini E, Di Cristo G, Avoli M. Dysregulation of GABAergic Signaling in Neurodevelomental Disorders: Targeting Cation-Chloride Co-transporters to Re-establish a Proper E/I Balance. Front Cell Neurosci 2022;15:813441. [DOI: 10.3389/fncel.2021.813441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Löscher W, Kaila K. CNS pharmacology of NKCC1 inhibitors. Neuropharmacology 2021;:108910. [PMID: 34883135 DOI: 10.1016/j.neuropharm.2021.108910] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]